Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Shortening Treatment by Advancing Novel Drugs
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 284
- Registration Number
- NCT02342886
- Locations
- 🇹🇿
Kilimanjaro National Institute for Medical Research, Mwanza, Tanzania
🇿🇦TASK, Bellville, Cape Town, South Africa
🇺🇬Uganda CWRU Research Collaboration, Kampala, Uganda
Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 22
- Registration Number
- NCT02308748
Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 67
- Registration Number
- NCT02283788
- Locations
- 🇺🇸
Comprehensive Phase OneTM, Miramar, Florida, United States
A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT02271438
Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02262546
Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT02257398
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT02256735
Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 81
- Registration Number
- NCT02248883
The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 208
- Registration Number
- NCT02243241
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Study of the Electrocardiographic Effects of TA-8995
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 136
- Registration Number
- NCT02241759
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.